DTxDM East

September 25-26, Boston, MA

Defining Validated Digital Interventions

DTxDM East Partners
Partners

Key Numbers of DTxDM

Attendees

Join over 200 senior decision-makers from DTx/DM companies, pharma, investors, payers and HCP’s.

Expert Speakers

Hear from the pioneers and most exciting newcomers as they present the latest clinical updates and discuss the critical opportunities.

Hours of Networking

Meet with exec’s and directors from the leading companies and future players through a multitude of networking opportunities.

Is DTxDM East For You?

DTxDM East has been constructed by the pioneers of the industry to serve as the dedicated meeting point for those pushing the boundaries, as well as those seeking to understand the fundamentals of the field.

As Digital Therapeutics and Digital Medicine continue on their exponential trajectory of development and hype, there is an undeniable need for the crucial business-model, reimbursement and regulatory opportunities to be discussed. DTxDM East will bring together DTx/DM companies, pharma, investors, payers and HCP’s to yield genuine outcomes on these hurdles through an open and collaborative forum.

This exec-level gathering of trailblazers and those looking to ascertain their play in this space will build upon the industry-defining discussions at DTxDM West. From influencing definitions and investment conversations, all the way through to adoption and impact on patients, DTxDM East is the end-to-end forum to help steer the future direction of this rapidly emerging industry.

Whether it’s through data-driven case studies, interactive panels or breakout workshops, attendees will gain unprecedented insights into the digital interventions set to revolutionize healthcare. Coupled with unprecedented networking opportunities to meet the movers and shakers, DTxDM East is the perfect size to make crucial connections and initiate partnerships.

Expert Speaker Faculty

Brandon Masterson

CEO, 2Morrow, Inc.

Brandon takes an analytical, problem-solving approach to addressing the largest culprits in today's healthcare challenges. From healthy living and effective coping skills to medical compliance, much of our healthcare woes are the result of individual behaviors. When founding 2Morrow, he saw the potential for the omnipresent smartphone and its rich technology stack to change how healthcare is delivered. As a developer, technology leader and early innovator in habit formation, Brandon has broad experience including the highly regulated medical device world, applied machine-learning and the power of technology and data to both inform organizations and influence individual behaviors. With the smartphone, he saw the potential to expand the reach of healthcare by putting these powerful tools directly into the hands of patients and the public. 2Morrow is an evidence-based, digital therapeutic company focused on behavior modification.

Pierre Leurent

CEO, Voluntis

Pierre Leurent, CEO and founder of VOLUNTIS, has more than 19 years of international experience in digital health in the United States and Europe. Voluntis’ mission is to improve the real-world value of therapies by providing patients and clinicians with therapeutic companion software. Its clinical-grade, regulatory-cleared mobile and cloud solutions embed advanced real-time decision support algorithms to enable patients to better manage their treatment in remote collaboration with their healthcare team. Prior to starting Voluntis in 2001, Pierre worked at GE Medical Systems, where he took part in the development of medical imaging software. He also occupied several positions at HealthCenter Internet Services, a San Francisco-based vendor of electronic medical record solutions.

Melinda Decker

Head, Oncology & Immuno-Oncology, Intelligent Pharmaceuticals, AstraZeneca

Melinda Decker is a passionate leader with a rare mix of both commercial and R&D expertise, developed over nearly 20 years in the pharmaceutical-biotech industry. She has broad therapeutic experience with biologic, small molecule and digital health products, across both specialty and primary care, and with both global and local markets. She currently is the Oncology TA Head for Intelligent Pharmaceuticals, AstraZeneca’s digital therapeutics team, focused on improving patient outcomes through digital health. In this role, she works to integrate medicines with technology such as connected devices, sensors, and smart packaging across the entire development cycle of launched, pre-launched and pipeline products. She holds an MS in Biochemical Engineering and an MBA in Finance and Marketing.

Joel Sangerman

Chief Commercial Officer, Click Therapeutics

Joel serves as Chief Commercial Officer for Click Therapeutics. Click develops software as prescription medical treatments to improve the lives of patients throughout the world.

For over 25 years Joel has helped payers, employers, providers and suppliers achieve better patient outcomes at a lower cost of care using new health technology. Helping to lead the charge for healthcare innovation, Joel will share how employers, insurers, and other healthcare payers are adopting Click’s clinically-validated digital therapeutics as key components to population health strategies.

While at Johnson & Johnson as Director of Payer Relations and with Walgreens as Vice President of Market Development Joel initiated pay for performance and shared savings models of value-based purchasing with payers and health systems. Joel also led commercial efforts with Sanofi Aventis to help providers contain the exploding costs associated with chronic conditions such as diabetes and cardiovascular disease.

Joel graduated from DePaul University in Chicago and later completed a Fellowship in healthcare leadership with the Washington DC based Advisory Board Company.

Eddie Martucci

CEO, Akili Interactive Labs

Eddie co-founded Akili Interactive Labs, and as part of PureTech has co-founded two other health-focused start-ups, and helped launch their digital health initiative. He was previously a Kauffman Entrepreneur Fellow, a program sponsored by the Kauffman Foundation of Kansas City, MO, focused on healthcare entrepreneurship. Prior to that, he completed his graduate work at Yale University in the Departments of Pharmacology and Molecular Biophysics & Biochemistry, focusing on structure-based drug design, where he led a research project that identified two novel chemical scaffolds as proof-of-concept compounds for novel therapy. Eddie received his B.S. in Biochemistry from Providence College, and his M.Phil. and Ph.D. from Yale University.

Debra Reisenthel

CEO, Palo Alto Health Sciences

Debra is founding CEO of Palo Alto Health Sciences, a digital therapeutic company providing evidence-
based, at-home, drug-free solutions in behavioral health. Freespira® is an FDA-cleared treatment for
panic disorder, panic attacks and symptoms of panic.

Debra has broad operational and leadership experience in start- ups as well as large corporations. Prior to PAHS, Debra worked with a Bay Area incubator to develop a women’s health product, was founding CEO of Novasys Medical, and was VP/GM of a Division of Tyco, inc. (Mallinckrodt, Nellcor).

Debra holds an MBA and R.R.T credentials. She has been a guest entrepreneur for 5 years as part of a Harvard Business School case study and supports entrepreneurs through her work with Astia and with CSweetner as a mentor to female executives.

Edward Cox

CEO, Dthera Sciences

Edward Cox was appointed as the new Chairman of the Board and the Chief Executive Officer of Dthera in connection with the closing of the EveryStory Transaction. Mr. Cox also continues to serve as EveryStory’s President and Chief Executive Officer and Chairman and a member of EveryStory’s Board of Directors, positions he has held since February 6, 2015. Prior to that, he served as a Vice President and Executive Officer of Apricus Biosciences, Inc., a publicly traded company, since December 2009, in roles leading Commercial Development, Business Development, Investor Relations, and Corporate Development. Mr. Cox holds a Master of Science in Management degree from the Warrington College of Business Administration at the University of Florida.

Kevin McRaith

CEO, WellDoc

As CEO, Kevin has led the WellDoc® team in the successful launch and continued development of the digital therapeutic for people living with type 2 diabetes, BlueStar®. Under his leadership, WellDoc has expanded its suite of BlueStar products to include: BlueStar® Rx, BlueStar® and BlueStar® C. Kevin oversees all WellDoc business related to enterprise strategy and has engineered an innovative commercial approach to position BlueStar in the marketplace to attract key investors and partnerships that include, Johnson & Johnson, Samsung and Merck GHI.

Matthew Stoudt

CEO, AppliedVR

Joris van Dam

Executive Director, Head of Digital Therapeutics Novartis

Joris van Dam is a Digital Health intrapreneur with 15 years’ experience in Pharmaceutical Research & Development, focusing on the innovative use of digital technologies to improve and transform therapeutic innovation, patient engagement, and clinical trials operations. Joris is currently leading the Digital Therapeutics initiative at Novartis Institutes for BioMedical Research, including its collaboration with Pear Therapeutics on the development of therapies in schizophrenia and multiple sclerosis.

Prior to that, Joris launched a number of digital health innovation initiatives at Novartis, including the launch of the Trials of the Future program, the Patients-2-Trials Consortium (a pharma consortium project to facilitate clinical research navigation for patients), the Clinical Research Collaboration with Walgreens (running interventional clinical trials at local Walgreens Healthcare clinics), TriNetX (a platform for using electronic medical records for study planning and design), CentrosHealth (a platform for patient engagement Apps in clinical trials), and a mobile platform for bedside data collection for clinical trials in Africa.

Prior to joining Novartis, Joris spent 7 years at Janssen, where a.o. he worked in partnership with the Bill and Melinda Gates Foundation to launch a mobile health platform for improving treatment of HIV patients in various regions across India, and led Janssen’s participation to the EHR4CR program at the EU’s Innovative Medicines Initiative (IMI). Prior to joining pharmaceutical research and development, Joris spent 7 years in consulting across industries and across Europe. Joris holds a PhD in Artificial Intelligence from the University of Amsterdam.

Sasha Said

Growth Equity Investor, Leerink Transformation Partners

LTP is a $313M growth equity fund investing exclusively in digital health and healthcare services. Sasha K. Said is a founding member of the LTP investment team where she sources and structures deals; provides representation for LTP on the Board of Directors; and provides strategic and tactical support to portfolio companies. She has 10 years of investing experience across asset classes, 4 of which were spent with Waypoint Capital, the multi-billion dollar investment group that represents the Bertarelli family. While there she helped launch a $2B life science fund, Gurnet Point Capital, now managed by Chris Viehbacher (former CEO of Sanofi), as well as built their corporate venture group with a strategy in digital health. Prior to Waypoint, Sasha was a Global Long/Short Public Equity and Private Equity Analyst at Water Asset Management, a global hedge fund in New York City.

Sasha serves as a Board Observer on the Boards of Vera Whole Health and Health Catalyst and is a Board Member of Rimedio, an early stage pharma services company. She is founder of Breaking7% (B7), a group of 122 women (51% senior/ 49% junior) in deal making roles in Boston who meet monthly to exchange deals and contacts. She is also an Advisor to Pulse companies, Massachusetts’ digital health accelerator.

Frank McGillin

Chief Commercial Officer, Neurometrix

Frank is Chief Commercial Officer at Neurometrix where he is leading the creation of new therapeutic category with the launch of Quell™ Wearable Pain Relief Technology, an FDA cleared, 100% drug free alternative for managing chronic pain. Quell was winner of the 2016 SXSW Innovation Award for Wearable Technology one of four health and fitness finalist for the Best of CES. After a successful crowdfunding campaign on Indiegogo, Quell is now available online and through major US retailers including Amazon, CVS, Best Buy and others. Quell has been covered extensively in national media including Good Morning America, CBS News, Forbes, Fortune, Wired and Men’s Health.

Frank has over 20 years of experience building successful, high-growth consumer health and technology brands at Philips and Johnson & Johnson, launching over 50 new products and leading global expansion of Sonicare. He has a passion for innovation in digital health.

Gregory Dodell, MD

Assistant Clinical Professor of Endocrinology, Diabetes and Bone Disease The Mount Sinai Hospital

Gregory Dodell, MD FACE is a board-certified endocrinologist. He received his medical degree from Albany Medical College. He completed his internal medicine and endocrinology Fellowship at St. Luke’s-Roosevelt Hospital Center, affiliated with Columbia University. He is an Assistant Clinical Professor of Medicine, Endocrinology, Diabetes and Bone Disease at the Icahn School of Medicine at Mount Sinai. He is the President of Central Park Endocrinology, PC.
Seth

Seth Feuerstein

CIO & CMO, Medical & Digital Innovation, Magellan Health

Seth Feuerstein is the chief medical officer of medical and digital innovation at Magellan Healthcare. In this role, he leads the development of effective business and clinical programs that leverage technology in several areas. Feuerstein, a psychiatrist by training, most recently developed Cobalt, a virtual therapeutic program which addresses 90 percent of behavioral health disorders. Feuerstein developed this virtual care platform to achieve better health, better care, and lower costs. With its acquisition of Cobalt, Magellan helps clients deliver online cognitive behavioral therapy to address problems such as anxiety, insomnia, depression, OCD and substance abuse.

David Amor

VP, Quality & Regulatory Affairs, Pear Therapeutics

David Amor is an FDA/ EU Quality/ regulatory expert focused on combination products and digital health. From NDAs and 505(b)(2)s to mobile app 510(k)s and Pre-INDs/ Q-subs, David has worked with over 45 medical device and pharmaceutical companies – large and small alike- supporting and/ or leading regulatory submissions and implementing quality management systems, including alignment of Agile-based SDLC programs to FDA and EU requirements. He co-founded RemindTrac in 2014 (www.remindtrac.com), a digital health company for chronic patients, that continues to pioneer mobile care management systems today, and sold his consulting firm Medgineering in 2016.

David has recently led QA/RA strategy groups at Teva within the Digital Health Group, particularly in development of Agile-based Quality Management Systems, was a Principal Consultant in the CP/DH (Combination Products, Digital Health) group at Qara Partners, and served as the in-house risk management subject matter expert at Abbott (St. Jude Medical). He has served as the Director or VP of Quality at other medical device start-ups including AdrenaCard, Calcula, Enspero Medical and various others, and led multiple organizations through 483 and Warning Letter remediation projects, namely associated with risk management and design history file deficiencies, including Pfizer (Hospira), MID, Boston Scientific and St. Jude Medical.

Ruchita Sinha

Senior Director of Investments, Sanofi Ventures

Ruchita Sinha is Sr. Director of Investments at Sanofi Ventures where she invests in biopharma and digital health opportunities. She led Sanofi’s investments in Inozyme, Omada Health, Evidation Health, Curisium, and also manages investments in Science 37 and Common Sensing. Prior to Sanofi, Ruchita was at GE Ventures, where she served as a board observer for HeadSense Medical and Caremerge and managed GE’s investments in CheckCap (Nasdaq: CHEKU) and HeartFlow. She also managed GE’s seed-stage portfolio of digital health investments in partnership with StartUp Health.

Ruchita has more than 15 years of healthcare experience in pharma, biotech, medical devices, and digital health. Previously, Ruchita was at Pfizer’s Strategy, BD, & Portfolio Management group, and a management consultant with LEK Consulting. Ruchita started her career with Maxygen, an early stage biotech company. She holds an MBA from the University of Chicago, an MS in Cellular and Molecular Biology from the University of Wisconsin-Madison, and a BS in Biochemistry from Mount Holyoke College.

Kevin Appelbaum

CEO, Better Therapeutics

Kevin is the co-founder and CEO of Better Therapeutics, a company developing prescription digital therapeutics for treating lifestyle-related diseases. He has been an active entrepreneur for more than 20 years, building and leading multiple transformative companies at the intersection of traditional consumer and healthcare industries. Earlier in his career, he was an executive with Procter & Gamble and PepsiCo, where he experienced first-hand that corporate food interests are not aligned with the best interests of individual health. He holds a B.S. in chemical engineering from the University of Pennsylvania. Following graduation, he served peacetime and combat assignments as an officer in the U.S. Army Rangers.

Kathryn Salisbury

Executive Vice President of Strategy and Business Development, MHA-NYC

Dr. Salisbury is Executive Vice President of Crisis and Behavioral Health Technologies and Strategic Planning at the Mental Health Association of New York City and has over 25 years of experience as a mental health clinician, administrator, educator, consultant and policymaker focusing on behavioral health issues. She has been instrumental in building MHA-NYC’s diverse portfolio of innovative programs and services, including workplace wellness programs, family support programs, disaster mental health services, and technology assisted behavioral health services.

Dr. Salisbury received a Ph.D. in Counseling Psychology and Ed.D. in Educational Policy Studies from the University of Massachusetts at Amherst. She is Assistant Clinical Professor of Psychology in Psychiatry at Yale University School of Medicine.

Alex Waldron

Chief Commercial Officer, Pear Therapeutics

Alex is a senior level global bio/pharmaceutical business leader with 27+ years of experience with large pharmaceutical, fully integrated biopharmaceutical and startup organizations. He has a proven record of building and leading business strategy and operations. In his career, Alex has driven enterprise value from portfolio strategy through to commercial launch. In previous roles, Alex has architected the structure and growth of several divisions at Biogen and helped to shape the emerging biosimilar market at Epirus Biopharmaceuticals. Alex has also worked in numerous commercial and operations roles at Genzyme, Astra Zeneca, Pfizer and Bristol-Myers Squibb.

Patrick James Lynch

CEO & Co-Founder, BelieveLTD

Believe Limited, a WEBBY-winning content agency. Patrick is the #1 social influencer in bleeding disorders and rare diseases and a leading expert in leveraging educational, narrative, podcast and documentary content to build deeply engaged, disease-specific audiences. Founding Board President, Entertainment to Affect Change (E2AC).

Konstantin Mehl

CEO, Kaia Health

Kaia Health Inc. was founded with the aim to create evidence-based applications for self-management of chronic diseases to reflect the growing evidence of patient empowerment with effective therapies. Treatments which place patients in the driver’s seat of disease management and offer non-pharmacological alternatives are rapidly gaining importance in almost any chronic illness- from pain conditions to neurodegenerative diseases.

Kaia aims to create interdisciplinary digital approaches that empower patients to take control of the management of their diseases at low costs and to democratize access to required lifestyle changes following onset of a chronic disease. To achieve this, Kaia brings together experts in each of the medical fields in the creation of content and applications. This approach is paired with technological innovations to increase patient motivation, ensure correct exercise execution and monitor disease activity. Kaia’s first app democratizes the access to the multimodal back pain therapy. Pilot studies have consistently shown enduring pain reduction in users. This effect is currently being reproduced in RCTs. Kaia’s late stage pipeline ranges from COPD to osteoarthritis and Parkinson’s.

Konstantin is a serial entrepreneur. His last company foodora, a global food delivery company was sold to delivery hero in 2015. He now builds a digital therapeutics company called Kaia Health. He holds a dual Masters in Finance and Energy Systems from Columbia University and a Bachelor’s degree from Technical University.

John Spinale

General Partner, Jazz Venture Partners

John currently is an investor and active advisor to many early-stage companies, in areas ranging from virtual reality (VR) platforms and content publishers to digital health apps for diagnosing and treating cognitive conditions like ADHD. John was most recently the General Manager of Disney’s (DIS) mobile and social games division, where he launched many chart topping titles while handling the full P&L for this multi-hundred million dollar business. John brings a deep understanding of creating innovative consumer experiences, building brands and leveraging new and emerging platforms to JAZZ. He is a proven leader in consumer technology and digital media with a career spanning nearly 20 years of building, scaling and running high-growth companies of all sizes, from initial seed through to late stage.

Jeff Mathers

Senior Director, Software Engineering & Emerging Technology, Johnson & Johnson Technology

Jeff is a proven technology architect and innovator with extensive experience in pharmaceutical R&D, medical device, and commercial software development. Currently Jeff manages a global team responsible for web, mobile, healthcare technology, business intelligence, analytics, platform architectures, software design, and solution delivery. In addition, his team is responsible for understanding and applying emerging technology to J&J business problems that will move the company forward in its quest to improve outcomes for patients.

Jo Masterson

Chief Operating Officer, 2Morrow, Inc.

Jo is fascinated by the convergence of mobile technology and behavioral science, especially surrounding the area of healthcare. At 2Morrow, Jo leads the research and program development efforts to make evidence-based behavior modifications programs more accessible by putting them directly in the hands of those who need them via their smartphones. Focused on drivers that affect chronic disease (i.e. smoking, weight, stress, chronic pain management), 2Morrow's evidence-based platform makes it easier and more convenient to include behavioral science into existing health care treatment plans. 2Morrow distributes programs distributed via employers, wellness platforms, health plans, providers and public health. Jo is a past ``40 under 40`` who started her career as a nurse and has worked in healthcare, education and technologies companies.

Eileen Rodgers

Director of VITAL Program, Highmark Health

Eileen Rodgers is director of the VITAL program for Pittsburgh-based Highmark Health, a national health and wellness organization and America’s second largest integrated financing and system (IDFS) based on revenue.

Ms. Rodgers joined the Highmark Health innovation team in 2016 to lead the VITAL program, a test- and- learn platform that can help propel new health solutions into the marketplace by providing the ideal environment for producing evidence. As part of the VITAL team, Eileen is passionate about bringing the best health innovations to our customers and ensuring that Highmark Health is seen as a next- generation leader in transforming care.

An accomplished organizational leader, Ms. Rodgers has focused her career on championing new solutions and initiatives that can transform the way customers interact with the healthcare system. In her current role, she has the unique opportunity to lead a high-performing team devoted to launching test and learns which gather valuable evidence that can lead to reduced medical spend, improved quality outcomes, and enhanced patient access to new technologies. Prior to joining Highmark Health, Ms. Rodgers worked at Highmark BCBS. During her 17 year tenure, she developed a passion for affecting a return on health for our customers and in accelerating valuable new health care solutions through key leadership roles in health plan operations, product development, and innovation.

Ms. Rodgers earned a Bachelor of Arts in Communications and Psychology from the University of Pittsburgh.

Eileen lives in Pittsburgh with her husband, Rick, three daughters, and cuddly pooch. She enjoys spending time with them, traveling to new locations, riding the latest roller coasters, watching movies, being outdoors, and reading for relaxation.

Brent Vaughan

CEO & Co-Founder, Cognoa

Brent is the CEO and co-founder of Cognoa, an AI-based digital precision medicine behavioral health platform. Cognoais developing innovative digital diagnostics and digital therapeutics to change the standard of care for pediatric behavioral health and improve outcomes by enabling earlier diagnosis, treatment, and increased engagement. Brent has over 20 years industry experience working with diagnostics, therapeutics and digital consumer health. Prior to Cognoa, Brent was the co-founder and COO of WellnessFX, an award-winning digital health company that increased patient engagement by providing direct-to-consumer diagnostics and integrated telemedicine. Before working in digital health, Brent worked in product and commercial roles in Novartis, Nektar, Roche and Lily.

Adam Kaufman

President & CEO, Canary Health

Adam Kaufman is a health pioneer, having led the building of digital behavior change programs used by dozens of healthcare organizations and tens of thousands of consumers. A health economist, engineer and company executive, Adam speaks to audiences nationwide on the accelerating trend of chronic illness, its impact on lives and costs of care and proven approaches to arresting disease trajectories.
Recognized as a leader in patient engagement and population health, Canary Health works with health plans such as Kaiser Permanente, Humana, GEHA and Blue Shield of California to empower members to better health self-management.

Everett Crosland

Head of Market Access & Reimbursement, Pear Therapeutics

Everett is the Head of Market Access & Reimbursement with Pear Therapeutics, a digital therapeutics company located in Boston, Massachusetts. At Pear, Everett leads payer strategy and engagement, pricing, reimbursement, HEOR, and government affairs. In past roles he has led the launch readiness and market access and reimbursement commercialization of infused, oral, drug-device combination, and digital therapies, and he has extensive experience managing pricing, payer, and reimbursement diligence for in-licensing, out-licensing, and buy-outs.

Joseph Glass

Assistant Investigator, Kaiser Permanente Washington Health Research Institute

Joe Glass, PhD, MSW, LICSW is an Assistant Investigator with Kaiser Permanente Washington Health Research Institute and an Affiliate Assistant Professor at the Department of Psychiatry and Behavioral Sciences of the School of Medicine at University of Washington. Dr. Glass was recently awarded a five-year career-development award from the National Institute of Health to study how to integrate digital treatments in healthcare settings. His research team is designing and testing strategies for implementing digital treatments for alcohol, opioid, and other substance use disorders in real-world primary care settings. He is known in his field for his work on brief interventions in healthcare settings. He is a licensed clinical social worker, and previously practiced at the US Department of Veterans Affairs in Ann Arbor, Michigan.

Swatee Surve,

Founder and CEO, Litesprite

Swatee Surve, Founder & CEO, is a leader who has developed and launched disruptive technology-based healthcare businesses for Microsoft, Nike, T-Mobile, Premera Blue Cross and Eastman Kodak. These commercialization projects led to several patents including Nike's first wearable technology patents. Surve has an MBA from the University of Chicago, an MSME in Biomechanics from Pennsylvania State University, and a BS in Bioengineering from the University of Illinois at Chicago. She has been featured in international, national, and regional media outlets including Huffington Post, International Business Times, NPR’s KUOW’s Morning Edition, APM: Marketplace, VentureBeat, Kauffman Foundation, and iMedicalapps.


Cris de Luca

Global Director, Digital Innovation, Johnson & Johnson Innovation

Tim Pearce

Manager, Market Research and Strategy, Stella/Blue Cross and Blue Shield of Minnesota

Tim leads market research and strategy for Stella’s Innovation Lab, a small team that invests in and builds healthcare products and services. Stella is the parent company to a diverse set of health companies including Blue Cross Blue Shield of Minnesota, Further, Learn to Live, and Livio Health, which affords a unique opportunity to accelerate the growth of health innovations through these channels. Tim is an active advisor in the digital therapeutics space and brings a wealth of knowledge regarding market sizing & segmentation, payer value prop development and commercialization strategies. Prior to working at Stella, Tim worked as a MedTech consultant, advising start-ups and Fortune 500 companies on market opportunities, barriers to adoption, and growth strategies and holds a B.S. and Ph.D. in Biomedical Engineering.

Yuri Maricich

Chief Medical Officer & Head of Clinical Development, Pear Therapeutics

Dr. Maricich leads the Clinical/Regulatory team at Pear Therapeutics as the Chief Medical Officer and Head of Clinical Development. He collaborates with the executive team on management and strategy. He leads and manages the clinical development programs from Discovery/TPP to Therapeutic, Translational, Clinical Development, through Regulatory submission and prosecution. He leads the team for Pear’s reSET clinical program, including the team and strategy for their De Novo Request/Submission of reSET to the FDA, which was cleared by the FDA as the first prescription digital therapeutic to treat disease. In addition to overseeing subsequent pipeline programs, including reSET-O (1st drug/software combination), Dr. Maricich leads Medical Affairs, responsible for successful coverage decisions and works closely with the Pear BD team on business development and biopharma deals and partnerships.

Summit Agenda

Download Agenda

Click to download our full event agenda.

8:00    Registration, Breakfast & Networking
9:00    Chairman’s Opening Remarks & Setting the Scene

Ed Cox, Chief Executive Officer, Dthera Sciences

09:15    Fireside Chat: Pear Therapeutics and Novartis 

Yuri Maricich, Chief Medical Officer & Head of Clinical Development, Pear Therapeutics
Joris Van Dam, Executive Director, Head of Digital Therapeutics, Novartis 

10:00    Keynote Panel and Open Q&A: Pioneers’ Perspective – Deciphering the Commercial Opportunities for Digital Therapeutics and Digital Medicine

Adam Kaufman, Chief Executive Officer, Canary Health
Kevin McRaith, Chief Executive Officer, WellDoc
Pierre Leurent, Chief Executive Officer, Voluntis
Eddie Martucci, Chief Executive Officer, Akili Interactive

10:30    Morning Refreshments & Networking
Interactive Workshop Sessions

During these intimate breakout sessions, attendees will address some of the key themes surrounding Digital Therapeutics and Digital Medicine. The topics for the workshops will run twice so that attendees can attend two sessions and get maximum value from these crucial discussions! You are spoilt for choice!

11:00    Workshop Session A:
Workshop 1A
Digital Therapeutics and Digital Medicine 101
Workshop 2A
Understanding the Regulatory Pathways

David Amor, Vice President, Quality & Regulatory Affairs, Pear Therapeutics

Workshop 3A
Tackling the Current Reimbursement Hurdles
11:45    Workshop Session B: Time to switch! 
Workshop 1B
Digital Therapeutics and Digital Medicine 101
Workshop 2B
Understanding the Regulatory Pathways

David Amor, Vice President, Quality & Regulatory Affairs, Pear Therapeutics

Workshop 3B
Tackling the Current Reimbursement Hurdles
12:30    Networking Lunch
Digging Deeper: Clinical Evidence Showcase

Observe as some of the leading companies in this space showcase their robust clinical data for your eyes only. With 20 minute presentations, questions will be held off until speakers reconvene on the Q&A panel that follows…let’s really dig deep and tackle the critical questions surrounding clinical validation for Digital Therapeutics and Digital Medicine.

1:30   Clinical Case Study 1: Behaviours & Chronic Diseases

Jo Masterson, Chief Operating Officer, 2Morrow, Inc.

1:50    Clinical Case Study 2: Autism

Brent Vaughan, Chief Executive Officer, Cognoa, Inc.

2:10    Clinical Case Study 3: Chronic Back Pain

Konstantin Mehl, Chief Executive Officer, Kaia Health

2:30    Interactive Panel and Open Q&A: Innovative Clinical Validation Models – What are they and how are they being Developed?

Brandon Masterson, Chief Executive Officer, 2Morrow, Inc.
Brent Vaughan, Chief Executive Officer, Cognoa, Inc.
Konstantin Mehl, Chief Executive Officer, Kaia Health

3:15    Afternoon Refreshments & Networking
Stakeholder Perspectives: Pharma & Investors
3:45    Interactive Panel and Open Q&A: Analyzing Pharma’s Short-Term and Long-Term Goals for Digital Medicine

Melinda Decker, Head of Oncology & Immuno-Oncology, Intelligent Pharmaceuticals, AstraZeneca
Jeff Mathers, Senior Director, Software Engineering & Emerging Technology, Johnson & Johnson Technology
Joris van Dam, Executive Director, Head of Digital Therapeutics, Novartis

4:25    Interactive Panel and Open Q&A: What is the current Investor Sentiment towards Digital Therapeutics & Digital Medicine?

Sasha Said, Growth Equity Investor, Leerink Transformation Partners
John Spinale, General Partner, Jazz Venture Partners
Cris de Luca, Global Director, Digital Innovation, Johnson & Johnson Innovation
Ruchita Sinha, Senior Director of Investments, Sanofi Ventures

Digital Showcase: Emerging Technology & Strategies
5:05    Disruptive Content in Rare Disease & Digital Medicine

Patrick James Lynch, Chief Executive Officer & Co-Founder, BelieveLTD

5:15    Neurotech in Focus: Applying Digital Therapeutics and Wearable Technology to Chronic Disease

Frank McGillin, Chief Commercial Officer, Neurometrix

5:25    Drinks Reception
Download Agenda to access full details of the event…
Download Agenda
8:00    Breakfast & Networking
9:00   Chair’s Opening Remarks

Joel Sangerman, Chief Commercial Officer, Click Therapeutics

Decisive Debates: Payer & Healthcare System Incentives 
9:10     Interactive Panel and Open Q&A: Payer Perspective – An honest look at Digital Therapeutics and Digital Medicine

Everett Crosland, Vice President, Market Access, Reimbursement & Government Affairs, Pear Therapeutics
Debra Reisenthel, Chief Executive Officer,  Palo Alto Health Sciences
Steve Cutts, Vice President, Pharmacy Services & Clinical Strategy,  Magellan Rx Management
Eileen Rodgers, Director of VITAL Program, Highmark Health
Tim Pearce, Market Research & Strategy, Stella / Blue Cross and Blue Shield of Minnesota

10:00   Interactive Panel and Open Q&A: Building the Ecosystem – Frontline Stakeholder Perspectives

Seth Feuerstein, Chief Innovation Officer & Chief Medical Officer, Medical & Digital Innovation, Magellan Health
Gregory Dodell, MD, FACE, President of Central Park Endocrinology, Assistant Clinical Professor of Endocrinology, Diabetes & Bone Disease,  The Mount Sinai Hospital
Kathryn Salisbury, Executive Vice President of Strategy & Business Development, MHA-NYC
Joseph Glass, Assistant Investigator, Kaiser Permanente Washington Health Research Institute 

10:45   Morning Refreshments & Networking
Digging Deeper: Deciphering the Business Models

Hear from some of the pioneers in this space, all implementing successful yet differing business models to get their products to market. Similar to the clinical evidence showcase yesterday, questions will be held off until speakers reconvene on the Q&A panel that follows lunch, allowing enough time to dig deeper into these go-to-market strategies.

11:15    Case Study 1: Presentation by AppliedVR

Matthew Stoudt, Chief Executive Officer, AppliedVR

11:35    Case Study 2: Targeting Employers & Health Plans

Joel Sangerman, Chief Commercial Officer, Click Therapeutics

11:55    Case Study 3: Presentation by Litesprite

Swatee Surve, Founder & Chief Executive Officer, Litesprite

12:15    Case Study 4: “Prescription Digital Therapeutics”

Kevin Appelbaum, Chief Executive Officer, Better Therapeutics

12:35    Networking Lunch
Business Models and Looking Ahead
1:35    Closing Panel and Open Q&A: Leading Business Models and the Future of the Industry

Swatee Surve, Founder & Chief Executive Officer, Litesprite
Matthew Stoudt, Chief Executive Officer, AppliedVR
Kevin Appelbaum, Chief Executive Officer, Better Therapeutics
Alex Waldron, Chief Commercial Officer, Pear Therapeutics

2:25    Chairman’s Summary

Joel Sangerman, Chief Commercial Officer, Click Therapeutics

2:35    Close of DTxDM East 2018
Download Agenda to access full details of the event…
Download Agenda

DTxDM East Venue

Battery Wharf Hotel, Boston Waterfront.

The summit is being held in the Battery Wharf Hotel, a luxury urban resort on the Boston Waterfront. The main conference sessions take place in the inspiring Harbourview which offers plenty of natural daylight.  We’ve arranged some great space for meetings and networking and (weather permitting) lunch on the harborside patio.

Getting to the venue could not be easier, you can even take the water taxi from Logan airport directly to the hotel dock.

Details of our exclusive delegate rates will be included in the welcome pack.

Registration

Sponsorship

The digital therapeutic and digital medicine landscape is on the cusp!

Projected to be worth $9.4bn by 2025, momentum has been gathering at an ever increasing rate, fueled by an influx of capital, clinical validation and top talent. The result is a market explosion, rife with ferocious dealmaking.

DTxDM East is the second edition in this acclaimed series, following on from the sold-out “Digital Therapeutics & Digital Medicine Summit” that took place in San Jose last February.

The conversations started on those two days, the meetings taken and the introductions made – these will form the basis for the next wave of funding, the next wave in partnering and ultimately, the next wave in innovation.

Talk to us today to discuss how you wish to be positioned as this market continues to surge forward.

Contact Us

Register For The Event

For pricing and booking options please click the button to go to the registration page.
Registration